Circulating microparticles from pulmonary hypertensive rats induce endothelial dysfunction

Simon Tual-Chalot1, Christelle Guibert, Bernard Muller

  • 1CNRS UMR 6214, Faculté de Médecine, Rue Haute de Reculée, Angers, F-49045 France.

Abstract

Insights

Hypoxic microparticles (MPs) increase in pulmonary arterial hypertension (PAH), causing endothelial dysfunction by reducing nitric oxide (NO) production. These MPs show tissue specificity, increasing oxidative stress only in pulmonary endothelial cells.

Area of Science:

  • Cardiovascular Research
  • Endothelial Biology
  • Pulmonary Hypertension

Background:

  • Pulmonary arterial hypertension (PAH) involves increased pulmonary vascular resistance and arterial remodeling.
  • Microparticles (MPs) are implicated as vectors of endothelial dysfunction in various diseases.

Purpose of the Study:

  • Characterize circulating MPs in hypoxic PAH models.
  • Investigate the impact of MPs on endothelial function.

Main Methods:

  • Rats exposed to chronic hypoxia to induce PAH.
  • Characterization of normoxic and hypoxic MPs via flow cytometry.
  • In vitro incubation of endothelial cells (ECs) with MPs.
  • Analysis of nitric oxide (NO) and reactive oxygen species (ROS) pathways.
  • In vivo assessment of endothelium-dependent relaxation.

Main Results:

  • Hypoxic rats exhibited a twofold increase in circulating MPs.
  • MPs from hypoxic rats reduced NO production in aortic and pulmonary ECs by enhancing eNOS phosphorylation.
  • Hypoxic MPs elevated oxidative stress specifically in pulmonary ECs via xanthine oxidase and mitochondrial pathways.
  • In vivo administration of hypoxic MPs impaired endothelium-dependent relaxation in both aorta and pulmonary arteries.

Conclusions:

  • Circulating MPs in hypoxic PAH induce endothelial dysfunction by decreasing NO bioavailability.
  • MPs exhibit tissue specificity, exacerbating oxidative stress predominantly in pulmonary ECs.
  • These findings highlight MPs as key players in PAH-associated endothelial dysfunction.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...